BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

170 related articles for article (PubMed ID: 16846803)

  • 1. Multipotent antioxidants: from screening to design.
    Zhang HY; Yang DP; Tang GY
    Drug Discov Today; 2006 Aug; 11(15-16):749-54. PubMed ID: 16846803
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Fragment-based drug design: combining philosophy with technology.
    Bartoli S; Fincham CI; Fattori D
    Curr Opin Drug Discov Devel; 2007 Jul; 10(4):422-9. PubMed ID: 17659483
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Scaffold composition and biological relevance of screening libraries.
    Shelat AA; Guy RK
    Nat Chem Biol; 2007 Aug; 3(8):442-6. PubMed ID: 17637770
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Discovery of a new drug--from target identification to ultra-high-throughput screening.
    Golz S; Hüser J
    Clin Lab; 2007; 53(1-2):77-9. PubMed ID: 17323829
    [No Abstract]   [Full Text] [Related]  

  • 5. Recent trends in library design: 'rational design' revisited.
    Schnur DM
    Curr Opin Drug Discov Devel; 2008 May; 11(3):375-80. PubMed ID: 18428091
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Design, synthesis, and biological evaluation of prazosin-related derivatives as multipotent compounds.
    Antonello A; Hrelia P; Leonardi A; Marucci G; Rosini M; Tarozzi A; Tumiatti V; Melchiorre C
    J Med Chem; 2005 Jan; 48(1):28-31. PubMed ID: 15633998
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Improved early clinical development through human microdosing studies.
    Wilding IR; Bell JA
    Drug Discov Today; 2005 Jul; 10(13):890-4. PubMed ID: 15993808
    [No Abstract]   [Full Text] [Related]  

  • 8. Drug discovery and natural products: end of an era or an endless frontier?
    Li JW; Vederas JC
    Science; 2009 Jul; 325(5937):161-5. PubMed ID: 19589993
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The adult human brain in preclinical drug development.
    Dragunow M
    Nat Rev Drug Discov; 2008 Aug; 7(8):659-66. PubMed ID: 18617887
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Synthetic library design.
    Huwe CM
    Drug Discov Today; 2006 Aug; 11(15-16):763-7. PubMed ID: 16846805
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Use of high-content analysis for compound screening and target selection.
    Rausch O
    IDrugs; 2005 Jul; 8(7):573-7. PubMed ID: 15973566
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Rational approaches to natural-product-based drug design.
    Haustedt LO; Mang C; Siems K; Schiewe H
    Curr Opin Drug Discov Devel; 2006 Jul; 9(4):445-62. PubMed ID: 16889228
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo pharmacological disease models for psoriasis and atopic dermatitis in drug discovery.
    Petersen TK
    Basic Clin Pharmacol Toxicol; 2006 Aug; 99(2):104-15. PubMed ID: 16918710
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The ortho hydroxy-amino group: another choice for synthesizing novel antioxidants.
    Chen W; Guo P; Song J; Cao W; Bian J
    Bioorg Med Chem Lett; 2006 Jul; 16(13):3582-5. PubMed ID: 16621555
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Non-optical screening platforms: the next wave in label-free screening?
    Cooper MA
    Drug Discov Today; 2006 Dec; 11(23-24):1068-74. PubMed ID: 17129825
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibitors of FabI, an enzyme drug target in the bacterial fatty acid biosynthesis pathway.
    Lu H; Tonge PJ
    Acc Chem Res; 2008 Jan; 41(1):11-20. PubMed ID: 18193820
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preclinical drug discovery research and training at Vanderbilt.
    Lindsley CW; Weaver D; Jones C; Marnett L; Conn PJ
    ACS Chem Biol; 2007 Jan; 2(1):17-20. PubMed ID: 17243778
    [No Abstract]   [Full Text] [Related]  

  • 18. How to understand the dichotomy of antioxidants.
    Shen L; Ji HF; Zhang HY
    Biochem Biophys Res Commun; 2007 Oct; 362(3):543-5. PubMed ID: 17681279
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A review on antioxidants, prooxidants and related controversy: natural and synthetic compounds, screening and analysis methodologies and future perspectives.
    Carocho M; Ferreira IC
    Food Chem Toxicol; 2013 Jan; 51():15-25. PubMed ID: 23017782
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Towards improving compound selection in structure-based virtual screening.
    Waszkowycz B
    Drug Discov Today; 2008 Mar; 13(5-6):219-26. PubMed ID: 18342797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.